Heart Failure News and Research

RSS

Heart failure (HF) is a condition in which a problem with the structure or function of the heart impairs its ability to supply sufficient blood flow to meet the body's needs. It should not be confused with cardiac arrest or myocardial infarction.

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

The U.S. Food and Drug Administration Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular safety of rosiglitazone, as presented by the FDA and GlaxoSmithKline. Following this two day discussion, Takeda Pharmaceuticals North America, Inc. ("Takeda") underscores its position that ACTOS (pioglitazone HCl) offers an established safety profile regarding the risk of CV events in people living with type 2 diabetes.

16 Jul 2010

Activities of TAT fully consolidated into Geron

Geron Corporation today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology, are being fully consolidated into Geron.

15 Jul 2010

MD Buyline identifies top emerging technologies with highest impact

This release will explain how these important technologies encourage high utilization rates across multiple service lines, bringing value to hospitals. Reimbursement changes and hospital structure enable technology purchases to generate a sequence of changes throughout service lines and dramatically impact the bottom line.

15 Jul 2010

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

GlaxoSmithKline confirmed today that a joint advisory committee to the U.S. Food and Drug Administration (FDA) voted to allow Avandia to remain on the market. Committee members voted for recommendations ranging from making no changes to the current label, to revising the label with additional warnings and restrictions to withdrawal from the U.S. market.

15 Jul 2010

Trevena completes $35M Series B financing

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor biased ligands, announced today that it has completed a $35 million Series B financing. Existing investors Polaris Venture Partners and New Enterprise Associates led the round, with all other existing Trevena investors - Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company - also participating in the financing.

14 Jul 2010

Research provides better understanding of drugs used to treat, prevent cardiovascular disease

Using chemical labeling and mass spectrometry-based techniques, Mark Chance, PhD, director of the Case Western Reserve University School of Medicine Center for Proteomics and Bioinformatics and professor of physiology and biophysics; Sayan Gupta, PhD, instructor at the Case Center for Proteomics and Bioinformatics; and a research team from the University of Oxford, for the first time, were able to take a high resolution picture of the open state of a K+ channel, allowing them to comparatively analyze gating mechanisms important to heart function and nerve signaling - in addition these techniques have already permitted Case Western investigators to gain a deeper understanding of G-protein coupled receptors.

14 Jul 2010

New research shows Alzheimer's disease may increase risk of other potentially disabling health conditions

Having Alzheimer's disease may increase the risk of getting other potentially disabling health conditions, including seizures and anemia, according to new research presented today at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu, HI.

14 Jul 2010

FDA to decide on Avandia’s fate Wednesday

Avandia, a drug used as a treatment for type 2 diabetes was approved for use in 1999. However controversies have surrounded it since 2007 when a Cleveland Clinic cardiologist Steven E. Nissen published a study in the acclaimed New England Journal of Medicine that concluded that the drug significantly increased the risk for heart problems like heart attacks, heart failure and deaths.

13 Jul 2010

Combined behavioral interventions most effective way to reduce heart disease risk

Combining counseling, extended follow-up with a healthcare provider and self-monitoring of diet and exercise is the most effective way to help patients embrace lifestyle changes that can lower their risk for heart and blood vessel (cardiovascular) diseases, according to a scientific statement published in Circulation: Journal of the American Heart Association.

13 Jul 2010

Strategies to prevent HACs, reduce cost of care, improve patient experience discussed at QUEST National Meeting

As healthcare providers prepare for the implications of reform, the more than 200 hospitals participating in the QUEST: High Performing Hospitals collaborative are already achieving the goals of improving patient care and reducing costs.

13 Jul 2010

Mortality rate of heart failure patients at Loyola is 24% lower than national average

The 30-day mortality rate of heart failure patients at Loyola University Hospital is 24 percent lower than the national average, according to the latest data from the federal government's Hospital Compare report card.

13 Jul 2010

Behavioral change programs help lower risk for cardiovascular diseases: Scientific statement

13 Jul 2010

Sleep apnea may increase risk of heart disease and death by 68%: Study

Obstructive sleep apnea (OSA) that leads to snoring and is actually caused by frequent collapse of the airway during sleep makes it difficult for sufferers to breathe for periods lasting as long as 10 seconds. Severe sufferers may have 30 such apnoeic or breathless episodes per hour that can severely disrupt sleep.

13 Jul 2010

Efficacy data of Caldolor Injection in treating fever associated with falciparum malaria published

Cumberland Pharmaceuticals Inc. today announced that data supporting the efficacy of Caldolor in treating fever associated with falciparum malaria was published in the July edition of the peer-reviewed American Journal of Tropical Medicine and Hygiene. The study, which is the first to document an antipyretic effect of an injectable non-steroidal anti-inflammatory drug on fever caused by malaria, demonstrated that patients who received intravenous ibuprofen experienced a greater reduction in their temperatures than those who received placebo.

13 Jul 2010

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing and review the supplemental New Drug Application for SPRYCEL (dasatinib) for the treatment of adult patients with newly diagnosed chronic myeloid leukemia in chronic phase.

12 Jul 2010

First patient enrolled in Boston Scientific's MultiSENSE clinical trial

Boston Scientific Corporation today announced enrollment of the first patient in its MultiSENSE clinical trial. The trial is designed to evaluate multiple physiologic sensors in the Company's COGNIS cardiac resynchronization therapy defibrillators. Boston Scientific plans to use the trial data to help develop a clinical alert that identifies the early onset of worsening heart failure.

8 Jul 2010

New information about quality of care available in America's hospitals added to new HHS website

Important new information about the quality of care available in America's outpatient and emergency departments, including how well hospitals care for patients with heart attacks and protect outpatients from surgical infections was added to the new HHS website HealthCare.gov.

8 Jul 2010

Heart attack death rates drop in hospitals; CDC reports increase in colon cancer screening rate

USA Today: Hospital heart attack death rates fell, according to new Medicare data. "Death rates at 4,569 hospitals that treat Medicare patients who suffer heart attacks fell by almost half a percentage point, from a national average of 16.6% last year to 16.2%. Death rates for most hospitals ranged from about 14.5% to 17.9%. ...

8 Jul 2010

HQA applauds public availability of hospital quality information at Hospital Compare website

The Hospital Quality Alliance today applauded the public availability of new information on hospital quality of care at the Hospital Compare website. The HQA is a broad working group of hospitals, consumer representatives, physician and nursing organizations, employers and payers, oversight organizations and government agencies dedicated to improving health care quality and making useful and understandable information about hospital quality available to the public.

8 Jul 2010

Cardiac Concepts initiates enrollment in European trial of RespiCardia System for CSA

Cardiac Concepts, Inc., a developer of medical devices to treat Heart Failure patients who experience breathing disturbances during sleep, announced today enrollment of the first European patients in a Pilot Clinical Trial. The purpose of the Pilot Study is to understand the respiratory and cardiac benefits of the RespiCardia™ System when treating a breathing disorder known as Central Sleep Apnea (CSA) in Heart Failure patients.

8 Jul 2010

Heart Failure News and Research

Further Reading

ACTOS offers safety profile regarding risk of CV events in people with type 2 diabetes: Takeda

Activities of TAT fully consolidated into Geron

MD Buyline identifies top emerging technologies with highest impact

GSK confirms FDA advisory committees' vote to allow Avandia to remain on the market

Trevena completes $35M Series B financing

Research provides better understanding of drugs used to treat, prevent cardiovascular disease

New research shows Alzheimer's disease may increase risk of other potentially disabling health conditions

FDA to decide on Avandia’s fate Wednesday

Combined behavioral interventions most effective way to reduce heart disease risk

Strategies to prevent HACs, reduce cost of care, improve patient experience discussed at QUEST National Meeting

Mortality rate of heart failure patients at Loyola is 24% lower than national average

Behavioral change programs help lower risk for cardiovascular diseases: Scientific statement

Sleep apnea may increase risk of heart disease and death by 68%: Study

Efficacy data of Caldolor Injection in treating fever associated with falciparum malaria published

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

First patient enrolled in Boston Scientific's MultiSENSE clinical trial

New information about quality of care available in America's hospitals added to new HHS website

Heart attack death rates drop in hospitals; CDC reports increase in colon cancer screening rate

HQA applauds public availability of hospital quality information at Hospital Compare website

Cardiac Concepts initiates enrollment in European trial of RespiCardia System for CSA

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News